ONVO logo

Organovo Holdings (ONVO) Company Overview

Profile

Full Name:

Organovo Holdings, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 14, 2012

Indexes:

Not included

Description:

Organovo Holdings (ONVO) is a biotechnology company that creates 3D human tissues using advanced printing technology. Their goal is to improve drug testing and research by providing realistic tissue models, which can help in understanding diseases and developing new treatments.

Key Details

Price

$0.34

Annual Revenue

$109.00 K(-70.54% YoY)

Annual EPS

-$1.60(+19.19% YoY)

Annual ROE

-155.00%

Beta

0.10

Events Calendar

Earnings

Next earnings date:

Feb 7, 2025

Recent quarterly earnings:

Nov 8, 2024

Recent annual earnings:

May 28, 2020
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 19, 2020

Analyst ratings

Recent major analysts updates

Nov 25, 20 Raymond James
Outperform
Nov 25, 20 H.C. Wainwright
Buy
Nov 25, 20 Evercore ISI Group
Buy
Nov 25, 20 BTIG Research
Buy
Aug 8, 19 HC Wainwright & Co.
Neutral
Dec 13, 18 HC Wainwright & Co.
Buy
Nov 10, 17 Raymond James
Market Perform
Jan 25, 17 Raymond James
Outperform
Dec 15, 16 BTIG
Buy
Nov 28, 16 Evercore ISI Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
ONVO
globenewswire.comJanuary 6, 2025

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer.

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
ONVO
globenewswire.comNovember 20, 2024

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The meeting was held November 15-19, 2024 in San Diego, California.

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
ONVO
globenewswire.comNovember 13, 2024

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.

Nio stock poised for 42% gain on ONVO sales momentum
Nio stock poised for 42% gain on ONVO sales momentum
Nio stock poised for 42% gain on ONVO sales momentum
ONVO
invezz.comSeptember 26, 2024

Nio Inc (NYSE: NIO) opened more than 10% up on Thursday after a JPMorgan analyst issued a super bullish note in its favour. Nick Lai now sees upside in the EV stock to $8.0.

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
ONVO
globenewswire.comJuly 16, 2024

SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company's near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798.

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
ONVO
GlobeNewsWireMay 14, 2024

Organovo is scheduled to share information about its primary clinical-stage medication, FXR314, at DDW2024, taking place in Washington, D.C. from May 18-21, 2024.

Organovo's fatty liver disease drug meets main goal in mid-stage study
Organovo's fatty liver disease drug meets main goal in mid-stage study
Organovo's fatty liver disease drug meets main goal in mid-stage study
ONVO
ReutersApril 15, 2024

Organovo Holdings announced on Monday that its experimental drug for a certain type of fatty liver disease achieved the primary objective in a mid-stage trial, causing its stock to rise by almost 27% in premarket trading.

Organovo to Participate in the H.C. Wainwright Global Investment Conference
Organovo to Participate in the H.C. Wainwright Global Investment Conference
Organovo to Participate in the H.C. Wainwright Global Investment Conference
ONVO
GlobeNewsWireSeptember 8, 2023

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

FAQ

  • What is the ticker symbol for Organovo Holdings?
  • Does Organovo Holdings pay dividends?
  • What sector is Organovo Holdings in?
  • What industry is Organovo Holdings in?
  • What country is Organovo Holdings based in?
  • When did Organovo Holdings go public?
  • Is Organovo Holdings in the S&P 500?
  • Is Organovo Holdings in the NASDAQ 100?
  • Is Organovo Holdings in the Dow Jones?
  • When was Organovo Holdings's last earnings report?
  • When does Organovo Holdings report earnings?
  • Should I buy Organovo Holdings stock now?

What is the ticker symbol for Organovo Holdings?

The ticker symbol for Organovo Holdings is NASDAQ:ONVO

Does Organovo Holdings pay dividends?

No, Organovo Holdings does not pay dividends

What sector is Organovo Holdings in?

Organovo Holdings is in the Healthcare sector

What industry is Organovo Holdings in?

Organovo Holdings is in the Biotechnology industry

What country is Organovo Holdings based in?

Organovo Holdings is headquartered in United States

When did Organovo Holdings go public?

Organovo Holdings's initial public offering (IPO) was on February 14, 2012

Is Organovo Holdings in the S&P 500?

No, Organovo Holdings is not included in the S&P 500 index

Is Organovo Holdings in the NASDAQ 100?

No, Organovo Holdings is not included in the NASDAQ 100 index

Is Organovo Holdings in the Dow Jones?

No, Organovo Holdings is not included in the Dow Jones index

When was Organovo Holdings's last earnings report?

Organovo Holdings's most recent earnings report was on Nov 8, 2024

When does Organovo Holdings report earnings?

The next expected earnings date for Organovo Holdings is Feb 7, 2025

Should I buy Organovo Holdings stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions